Share This Page:   

 

Browse by Clinical Topic:
Select a Topic to Learn More

Featured CME/CE Content:

 

neuroscienceCME Editors' Picks:

Getting Ahead of irAEs: Fostering Change in Structural Systems for Disadvantaged Populations

Premiere Date: Monday, August 8, 2022

This activity offers CE credit for:

1. ABIM (MOC)
2. Medicine (accme)
3. Nursing (ANCC)
4. Pharmacy (acpe)
5. PA (aapa)
6. Other

All other clinicians will receive a Certificate of Attendance stating this activity was certified for AMA PRA Category 1 Credit™

Credit Expiration Date:
Tuesday, August 8, 2023
Note: Credit Is No Longer Available

Faculty

Ticiana Leal, MD (Moderator) Associate Professor of Medicine Department of Hematology and Oncology Director, Thoracic Medical Oncology Winship Cancer Institute Emory University Atlanta, GA

Aung Naing, MD, FACP  (he/him/his) Professor, Investigational Cancer Therapeutics The University of Texas MD Anderson Cancer Center Houston, TX Editor-in-Chief, Journal of Immunotherapy and Precision Oncology

Kristen Whitaker, MD, MS  Assistant Professor, Department of Medicine (Medical Oncology) Georgetown Lombardi Comprehensive Cancer Center Washington Hospital Center Washington, DC

Statement of Need

When health care professionals (HCPs) use shared decision-making (SDM) with patients, patient satisfaction and trust improve; however, if SDM is not culturally aligned, health care inequities may be exacerbated. When using immune checkpoint inhibitors (ICIs) in cancer care, SDM is vital to help identify and address adverse events (AEs). Participation by patients from under-represented groups in clinical studies for ICIs has been low, primarily due to the social determinants of health (SDoH), HCP bias, and medical mistrust resulting from historic injustices. Because data on AEs and the efficacy of ICIs in ethnic and racial minority groups is insufficient, clinicians must use SDM and build trust to connect with patients from underserved communities and reduce inequities in cancer care. Additionally, by increasing diversity in health care systems and using patient navigation services, as well as best practices and protocols, health inequities in the use of ICIs in cancer care can be addressed. Building trust is essential to improving patient outcomes and reducing immune-related adverse events (irAEs).

In this OnDemand webcast, expert faculty will discuss how to use SDM to communicate treatment options, including ICIs, and build trust with patients to improve outcomes. They will present an overview of ICIs, the indications for use and common AEs, and then outline best practices and protocols for patients taking ICIs. Finally, faculty will address how to diagnosis and manage AEs to provide better adherence to ICI therapies for all patients with cancer.

Learning Objectives

At the end of this CE activity, participants should be able to:

• Recommend improvements to structural systems to better support irAE management in historically disadvantaged patient populations.

Financial Support

Supported by educational grants from Bristol Myers Squibb and Merck Sharpe & Dohme Corp.

Target Audience

Physicians, PAs, nurse practitioners, nurses, nurse navigators, and pharmacists, specializing in oncology, emergency medicine and/or primary care

Credit Information

ABIM MOC Credit:
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.75 medical knowledge MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Learning Formats
Enduring material

Royal College MOC:
Through an agreement between the Accreditation Council for Continuing Medical Education and the Royal College of Physicians and Surgeons of Canada, medical practitioners participating in the Royal College MOC Program may record completion of accredited activities registered under the ACCME’s “CME in Support of MOC” program in Section 3 of the Royal College’s MOC Program.

MIPS Improvement Activity:
This activity counts towards MIPS Improvement Activity requirements under the Medicare Access and CHIP Reauthorization Act of 2015 (MACRA). Clinicians should submit their improvement activities by attestation via the CMS Quality Payment Program website.

It is the policy of CME Outfitters, LLC, to ensure independence, balance, objectivity, and scientific rigor and integrity in all of their CE activities. Faculty must disclose to the participants any relationships with commercial companies whose products or devices may be mentioned in faculty presentations, or with the commercial supporter of this CE activity. CME Outfitters, LLC, has evaluated, identified, and mitigated any potential conflicts of interest through a rigorous content validation procedure, use of evidence-based data/research, and a multidisciplinary peer review process. The following information is for participant information only. It is not assumed that these relationships will have a negative impact on the presentations.

Dr. Leal reports the following financial relationships:

Advisory Board: AstraZeneca; Bayer; Boehringer-Ingelheim; Blueprint Medicines Corporation; Daiichi-Sankyo, Inc.; Eisai Inc.; EMD Serono; Genentech, Inc.; Janssen Pharmaceuticals, Inc.; Jazz Pharmaceuticals, Inc.; Merck & Co., Inc.; Mirati Therapeutics, Inc.; and Takeda Pharmaceuticals U.S.A., Inc.

Consultant: Amgen Inc.; AstraZeneca; Boehringer-Ingelheim; Janssen Pharmaceuticals, Inc.; Jazz Pharmaceuticals, Inc.; Lilly; Novocure; and Roche

Grants: Pfizer Inc.

Dr. Naing reports the following financial relationships:

Research Support: Amplimmune, Inc.; Arcus Biosciences, Inc.; ARMO BioSciences, Inc.; Atterocor, Inc.; Baxalta (I); Bristol Myers Squibb Company; Calithera Biosciences, Inc.; Chao Physician-Scientist Awards (I), Baylor College of Medicine; CytomX Therapeutics, Inc.; EMD Serono Inc.; Healios Oncology Nutrition, LLC; Immune Deficiency Foundation (I); ImmuneOncia Therapeutics, Inc.; Incyte; Jeffrey Modell Foundation (I); Karyopharm Therapeutics; Kymab; MedImmune; Lilly; Merck & Co., Inc.; Neon Therapeutics; NeoImmuneTech; National Cancer Institute (NCI); Novartis; Pfizer Inc.; PsiOxus Therapeutics; Regeneron Pharmaceuticals In; Surface Oncology; and TopAlliance BioSciences Inc.

Other Financial or Material Support: (Travel, accommodations, expenses) ARMO Biosciences, Inc.

Dr. Whitaker reports the following financial relationships:

Consultant: Norvartis

Grants: The V Foundation for Cancer Research

Research Support: The V Foundation for Cancer Research and National Institutes of Health (NIH)

Other Financial or Material Support: Axis Medical Education and Total Health Conferencing

The following peer reviewer and CME Outfitters staff have no financial relationships:

Michael Franks, APRN, AGACNP-BC, FNP-BC (peer reviewer)

David Modrak, PhD (planning committee)

Kathleen Blake, PhD (planning committee)

Thomas Mitchell (planning committee)

Sandra Caballero, PharmD (planning committee)

Susan H. Yarbrough, CHCP (planning committee)

Sharon Tordoff (planning committee)

Faculty of this CE activity may include discussions of products or devices that are not currently labeled for use by the FDA. The faculty have been informed of their responsibility to disclose to the audience if they will be discussing off-label or investigational uses (any uses not approved by the FDA) of products or devices.

Questions about this activity? Call us at 877.CME.PROS (877.263.7767).